Results : Duloxetine may be an effective treatment for mood spectrum disorders , panic disorder , several symptom clusters of borderline personality , and as add-on drug in schizophrenia .
Modest or conflicting results have been found for the efficacy of duloxetine in obsessive-compulsive disorder , posttraumatic stress disorder , eating , and sexual disorders .
Background : Duloxetine hydrochloride ( DUL ) is an antidepressant included in the pharmacological class of serotonin-norepinephrine reuptake inhibitors approved for the treatment of major depressive disorder , generalized anxiety disorder , diabetic peripheral neuropathic pain , fibromyalgia , and chronic musculoskeletal pain .
The aim of this review was to eluci date current evidence s on the use of DUL in the treatment of a variety of psychiatric disorders .
Duloxetine treatment for women with premenstrual dysphoric disorder: a single-blind trial.
Premenstrual dysphoric disorder ( PMDD ) affects 3 - 8 % of women of reproductive age and is characterized by severe mood symptoms that cause important functional impairment . Serotonergic antidepressants appear to be an effective treatment for this disorder . The purpose of this study was to collect evidence on the efficacy and tolerability of duloxetine , a dual reuptake inhibitor of serotonin and norepinephrine , in the treatment of PMDD . We conducted a pilot , single-blind , non-controlled , fixed-dose trial . After two cycles for diagnosis confirmation , including a single-blind placebo cycle , 20 women with PMDD were treated continuously for three menstrual cycles with 60 mg/d duloxetine . The primary measure of the efficacy of treatment with duloxetine was the significant reduction in premenstrual symptoms demonstrated by the comparison between the mean Daily Record of Severity of Problems ( DRSP ) scores at baseline to endpoint ( p=0.0002 ) . Statistically significant symptom reduction was observed in the first treatment cycle and throughout all the treatment phase . Clinical response , defined as a reduction 50 % of baseline premenstrual symptoms , occurred in 65 % of subjects ( intention-to-treat population ) . Significant improvements were demonstrated by secondary measures , including reduction in self-rated functional impairment ( p=0.01 ) and improvement in quality of life ( p=0.04 ) . The main side-effects associated with duloxetine were dry mouth , nausea , drowsiness , insomnia , decreased appetite , decreased libido , and sweating . Duloxetine was effective and generally well tolerated in the treatment of PMDD . Further large-scale , double-blind , placebo-controlled studies are needed to evaluate duloxetine as an additional treatment strategy for the management of PMDD
Results : Duloxetine may be an effective treatment for mood spectrum disorders , panic disorder , several symptom clusters of borderline personality , and as add-on drug in schizophrenia .
Modest or conflicting results have been found for the efficacy of duloxetine in obsessive-compulsive disorder , posttraumatic stress disorder , eating , and sexual disorders .
Background : Duloxetine hydrochloride ( DUL ) is an antidepressant included in the pharmacological class of serotonin-norepinephrine reuptake inhibitors approved for the treatment of major depressive disorder , generalized anxiety disorder , diabetic peripheral neuropathic pain , fibromyalgia , and chronic musculoskeletal pain .
The aim of this review was to eluci date current evidence s on the use of DUL in the treatment of a variety of psychiatric disorders .